Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology/Urology
Disease Category: Renal Cell Carcinoma

Trial Information

A clinical trial evaluate the safety and efficacy of a study drug versus placebo in patients with a clear cell renal cell carcinoma and a high risk of recurrence

Summary
Wilex AG is conducting a clinical trial to evaluate disease free survival in subjects taking the study drug compared to those taking placebo in subjects who have a high risk of recurrence of clear cell renal cell carcinoma, post removal of kidney cell cancer.

To qualify, you must

• Have prior nephrectomy (removal of kidney or portion of kidney) of primary kidney cell cancer with documented clear cell cancer.
• At least 18 years old.

You will not qualify if you:

• Have evidence of residual disease
• Have had nephrectomy more than 12 weeks ago
• Have tested positive for HIV I and II as well as Hepatitis B or C
• Are pregnant or breastfeeding
• Have had prior organ transplantation
• Have received prior radiation, immunotherapy or chemotherapy within the last 5 years
• Have any other active or past cancer within the last 5 years (except non melanoma skin cancer, or cervical cancer)

For more information,

Susan Brockmeyer
Biomedical Research Alliance of New York
Urology Associates PC
535 Plandome Road
Manhasset, NY 11030
Phone: 516-627-6188

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.